Inside-Filings
Projekt anfragen

MAXCYTE, INC. (MXCT)

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (27.03.2026)
DatumMeldungSchwereFilingAuszug
27.03.2026Item 5.02 — Abgang SchlüsselpersonenHOCHSECange Act. ☐ ​ ​ ​ ​ ​ ​ ​ ​ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
11.08.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECxchange Act. ☐ ​ ​ ​ ​ ​ ​ ​ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
27.12.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSEC(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointm
15.10.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSECxchange Act. ☐ ​ ​ ​ ​ ​ ​ ​ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
12.06.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSEC3(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoin
26.01.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSEC3(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoint
11.12.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC3(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoint
23.06.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC          Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
28.03.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC          Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Stammdaten

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Unternehmen & Branche

NameMAXCYTE, INC.
TickerMXCT
CIK0001287098
BoerseUS
SektorHealthcare
IndustrieMedical - Devices
SIC8731 · Services-Commercial Physical & Biological Research

Wertpapier & Kennzahlen

CUSIP5777K1061
ISINUS5777K10615
TypCommon Stock
Marktkapitalisierung87,6 Mio. USD
Beta1,45
Dividendenrendite0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K33,026,000-44,630,000-0.42202,507,000171,490,000
2025-09-3010-Q6,829,000-12,416,000-0.12213,476,000180,275,000
2025-06-3010-Q8,507,000-12,357,000-0.12219,750,000190,723,000
2025-03-3110-Q10,390,000-10,261,000229,961,000199,412,000
2024-12-3110-K38,627,000-41,055,000-0.39239,470,000206,251,000
2024-09-3010-Q8,164,000-11,557,000-0.11248,612,000213,302,000
2024-06-3010-Q10,429,000-9,375,000-0.09251,496,000221,261,000
2024-03-3110-Q11,342,000-9,526,000257,930,000226,359,000
2023-12-3110-K41,288,000-37,923,000-0.37268,274,000232,167,000
2023-09-3010-Q8,004,000-11,251,000-0.11266,727,100233,378,000
2023-06-3010-Q9,043,000-10,512,000-0.10271,204,100240,983,000
2023-03-3110-Q8,576,000-10,882,000-0.11281,544,400247,819,000
2022-12-3110-K44,261,000-23,571,000-0.23286,653,000253,968,000
2022-09-3010-Q10,642,800-6,433,700-0.06286,411,900254,432,200
2022-06-3010-Q9,607,800-8,260,200-0.08289,776,600257,222,900
2022-03-3110-Q11,587,300-4,067,300-0.04290,955,200262,184,800
2021-12-3110-K33,894,100-19,082,200-0.21284,120,000262,899,000
2021-09-3010-Q10,139,100-2,680,400-0.03277,689,900264,115,900
2021-06-3010-Q7,108,100-4,421,800-0.0593,147,20078,821,200
2021-03-3110-Q6,494,900-7,105,600-0.0981,285,600

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

DatumInsiderRolleTypStückzahlKursWert (USD)ΔTrend
2026-03-17Swirsky Douglas JOfficer, CHIEF FINANCIAL OFFICEROpen Market Sale-10,1420.82-8,265.73-11,3%
2025-08-13Swirsky Douglas JOfficer, CHIEF FINANCIAL OFFICEROpen Market Purchase50,0001.2964,500.00+88,4%
2025-08-13Masoud MaherDirector, Officer, President and CEOOpen Market Purchase75,0001.37102,915.00+141,0%
2025-08-13DOUGLAS RICHARDDirectorOpen Market Purchase80,0001.39111,040.00+152,2%
2025-08-13Brooke William WDirectorOpen Market Purchase50,0001.2964,500.00+88,4%
2025-08-13Erck Stanley CDirectorOpen Market Purchase100,0001.37137,220.00+188,0%
2025-06-25Hemrajani RekhaDirectorOpen Market Sale-10,6842.09-22,377.64-30,7%

Top-Fondshalter

Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.03.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.

FondsAnteileWert (USD)Anteil (%)
AWM Investment Company, Inc.102,200279,006100.00

Hinweis

Erweitert ×